ERBB2 and breast cancer: Continuous assessment of the Notch-EGFR/HER2 signaling networks reveals that HER-driven breast cancer cells exploit the Notch pathway to sustain HER2-induced signaling via the PI3K pathway, enabling survival against HER2-targeted therapy (Baker et al., 2014).